ClinicalTrials.gg
Not yet recruitingNCT07310342ITP-CPETUpdated Dec 30, 2025

Physical Fitness of Children, Adolescents and Young Adults With Immune Thrombocytopenic Purpura

An interventional study of IPT-CPET in Immune Thrombocytopenic Purpura, sponsored by University Hospital, Bordeaux. Not yet recruiting at 5 sites in France. Open to participants aged 8 Years to 25 Years. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
8 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Purpura, Thrombocytopenic, Idiopathic by University Hospital, Bordeaux — 5 open to participants now, 5 under way, none of them phase 3. Purpura, Thrombocytopenic, Idiopathic · University Hospital, Bordeaux.

Started
2025
the only one that year
No phase
4 of 12
3 open now
Registered
11th of 12
by date

Among the 12 studies in Purpura, Thrombocytopenic, Idiopathic by University Hospital, Bordeaux, this one is the only one that started in 2025, is one of 4 with no phase, and was the 11th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 12 studies in Purpura, Thrombocytopenic, Idiopathic by University Hospital, Bordeaux are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 8 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Purpura, Thrombocytopenic, Idiopathic by University Hospital, Bordeaux, or all of them as a file.
02

Study summary

Patients with chronic immune thrombocytopenic purpura (ITP) live with an anxiety-inducing risk of haemorrhage that is unpredictable over several months or years.

They also rate fatigue as one of the most frequent (48%) and most severe (73%) disabling symptoms, which contributes to a reduced quality of life [Cooper, 2021].

In this autoimmune disease targeting platelets, fatigue could be mediated by platelet and immunological abnormalities, and/or promoted by psychobehavioural determinants that are poorly understood in this chronic disease.

Since 1980, the World Health Organisation has stated that functional capacity assessments best reflect the impact of chronic diseases on quality of life, with fatigue playing an important role. The association between fatigue and aerobic physical capacity, determined by maximum oxygen consumption (VO2max), has been demonstrated in several pathologies. It is often associated with the vicious circle of deconditioning, where the impact of the disease on cardiac, muscular and respiratory functions is intertwined with inactive or sedentary behaviours.

At the end of this vicious circle, adults have been shown to have an increased cardiovascular risk and a high prevalence of anxiety and depression syndromes.

VO2max measured by cardiopulmonary exercise testing (CPET) is increasingly used in monitoring, as recommended by the French Society of Cardiology [Marcadet, 2018;Marcadet, 2019]. Our team (Amedro et al.) has set up a research programme on aerobic physical capacity and deconditioning to exercise in chronic childhood diseases and has just published the reference values for exercise tests in healthy paediatric populations, enabling the interpretation of VO2max results in sick children [Gavotto,2023].

However, it has been demonstrated that the VO₂ plateau is not predominantly reached in healthy adults and is rarely reached (\<25%) in healthy children. [Armstrong, 1996 ; Åstrand, 1952 ; Rowland, 1992].

Thus, the highest oxygen consumption measurement (VO2pic) is often used instead of VO2max to define aerobic capacity. We will therefore use the concepts of VO2max and VO2pic in this study.

The first population studied by our team was children with congenital heart disease, who showed a significant reduction in their VO2max [Amedro, 2018]. Based on these results, a functional rehabilitation programme (QUALIREHAB) was set up and evaluated in a randomised controlled clinical trial [Amedro, 2019] . The data demonstrate its positive impact not only on VO2max, but also on quality of life. Aerobic physical capacity was assessed in chronic paediatric diseases without direct cardiac involvement.

We have also shown that VO2max declines more rapidly over time in children, adolescents and young adults who have survived childhood cancer [Gavotto, 2023] or in children with asthma [Moreau, 2023].

To date, no prospective controlled studies have reported on the level of aerobic physical capacity in children, adolescents and young adults with cITP.

We therefore hypothesise that fatigue in patients monitored for cITP could be correlated with a decrease in their aerobic physical capacity, causing these patients to enter a 'vicious cycle of deconditioning'. If this hypothesis is verified, an exercise rehabilitation programme could have a positive impact on quality of life, physical health and mental health

03

Conditions studied

  • Immune Thrombocytopenic Purpura

Keywords

  • Immune thrombocytopenic purpura (ITP)
  • Fatigue
  • Deconditioning
  • functional rehabilitation
04

Who can participate

Ages eligible
8 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children, adolescents and young adults aged 8 to 25 followed for ITPc
  • Patient referred as part of routine care by a CEREVANCE network expert physician to an exercise physiology laboratory for fitness assessment

Exclusion criteria

Exclusion Criteria:

  • Presence of at least one to performing an exercise test

    • Acute anemia \< 9g or poorly tolerated chronic anemia, fever, uncontrolled asthma, respiratory failure, acute myocarditis or pericarditis, uncontrolled arrhythmias causing symptoms or hemodynamic disturbance, uncontrolled heart failure, acute pulmonary embolism or pulmonary infarction,
    • Patients with mental impairment leading to an inability to cooperate, as assessed by the physician during the history,
    • Clinical examination abnormalities (heart murmur, rhythm disorders).
  • Opposition to participation expressed by the parent(s) or legal guardian(s) for minors (\<18 years) or by the patient.
  • Absence of social security
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (estimated)

Study arms

  • Experimental
    ITP group

    Children, adolescents and young adults aged 8 to 25 followed for ITPc (N=53)

    Other: IPT-CPET

Interventions

  • OtherIPT-CPET

    Patients with ITP will undergo standard care, medical examination, cardiopulmonary exercise test (CPET), muscular strength and physical activity tests, and validated questionnaires of health-related and disease-related quality of life, mental health, and physical activity

06

What researchers measure

Primary outcomes

  1. VO2max measured by exercise testing

    Values will be standardised using paediatric reference values.

    Time frame: Day 1

Secondary outcomes

  1. First ventilatory threshold (SV1)

    as a percentage of theoretical VO2max

    Time frame: Day 1

  2. Ventilatory efficiency

    VE/VCO2 slope

    Time frame: Day 1

  3. Maximal power

    Time frame: Day 1

  4. Oxygen pulse

    Time frame: Day 1

  5. Maximum heart rate

    Time frame: Day 1

  6. Respiratory exchange ratio

    Time frame: Day 1

  7. Respiratory reserve

    Time frame: Day 1

  8. Health-related quality of life

    PedsQL®

    Time frame: Day 1

  9. Disease-specific quality of life

    Kids ITP Tools

    Time frame: Day 1

  10. Muscular force evaluation

    Handgrip®

    Time frame: Day 1

  11. Muscular force evaluation

    standing long jump

    Time frame: Day 1

  12. Physical activity evaluation

    level of physical activity evaluated using an accelerometer

    Time frame: Between Day 1 and Day 7

  13. Physical activity evaluation

    * Children and Adolescents Physical Activity and Sedentary Questionnaire * International Physical Activity Questionnaire

    Time frame: Day 1

  14. Mental health evaluation

    * Strenghts and difficulties questionnaire * Adolescent Depression Rating Scale * Patient Health Questionnaire (PHQ-9)

    Time frame: Day 1

  15. Fatigue evaluation

    Fat-PTI questionnaire

    Time frame: Day 1

07

Study locations

5 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 30, 2025
StartEst.
Dec 15, 2025
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 22, 2026
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07310342
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Dec 15, 2025 (estimated)
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 22, 2026 (estimated)
Last update
Dec 30, 2025

Study contacts

Marion AUDIE, MD
Contact
marion.audie@chu-bordeaux.fr
+330557656465 ext. +33
Nathalie ALADJIDI, MD
Contact
nathalie.aladjidi@chu-bordeaux.fr
+33 05 57 82 02 61 ext. +33
Pascal AMEDRO, MD,PhD
study director · University Hospital, Bordeaux
Nathalie ALADJIDI, MD
study director · University Hospital, Bordeaux
Marion AUDIE, MD
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion